MRNA · Moderna Inc
Price
Snapshot
50 fields · last close| Market Cap | $61.50B |
| P/E | — |
| Float | 367.8M |
| Beta | 1.21 |
| Volatility | 30.2% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 15 |
| Price | 166.38 |
| Change | +8.01% |
| Prev Close | 154.04 |
| Open | 158.35 |
| Day Low | 150.26 |
| Day High | 159.79 |
| Avg Vol | 12 |
| Avg $ Vol | $1.92B |
| 52W High | 176.66 |
| 52W Low | 22.28 |
| 52W Pos | 93.3% |
| From High | −5.82% |
| From Low | +646.77% |
| Max DD 1Y | −34.16% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +14.04% |
| SMA 50 | +69.49% |
| SMA 200 | +176.14% |
| RSI (14) | 63.3 |
| Vol 30D | 315.3% |
| Vol 90D | 191.6% |
| 1Y Range | 22–177 |
| Daily bars | 516 |
| Perf Week | +6.99% |
| Perf Month | −11.66% |
| Perf Quarter | +140.84% |
| Perf Half Y | +194.14% |
| Perf Year | +516.16% |
| Perf YTD | +439.14% |
| Prev Day | +8.01% |
| Clavix | F |
| Debt / Eq | 0.07 |
| Curr Ratio | 3.29 |
| Int Cover | — |
| FCF Margin | 38.9% |
| Rev Growth | +2.1% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 35 / 35 |
What MRNA does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Clavix risk grade
regraded every trading dayMRNA grades F, 15 of 100. Steadiest on News Sentiment (52), most exposed on Price Stability (4, weak). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 35 of 35 in Biotechnology by Clavix score.
How rough the ride is
| MRNA | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.21 | 0.51 |
| Volatilityannualized | 30.2% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −34.2% | — |
| Typical daily movemedian absolute daily change | 2.51% | — |
| Days beyond ±3%of the last 252 sessions | 10843% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MRNA | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.21 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MRNA | |
|---|---|
| 1 week | +7.0% |
| 1 month | −11.7% |
| Year to date | +439.1% |
| 1 year | +516.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MRNA | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 28 Aug |
| Average score0 most bearish, 100 most bullish | 63 |
| Bullish · bearisharticles above 60 · below 40 | 20 · 6 |
| Directionarticles whose tone is improving vs worsening | 20 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| MRNA | |
|---|---|
| Revenue growthyear over year | +2.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openModerna's management appeared at the Morgan Stanley Global Healthcare Conference and discussed progress across its vaccine portfolio, including ongoing Phase 3 (late-stage) work on intismeran, a personalized cancer vaccine. The stock dropped 2.55% to $154.04 that day, but is up 6.99% over the past week and 140.84% over the past three months.
BioNTech and Roche's Genentech cancelled a mid-stage (Phase 2) trial of their mRNA colorectal cancer vaccine after it failed to work well enough, ending the program. The article notes BioNTech's stock had previously jumped when Moderna and Merck reported positive late-stage results for their own personalised mRNA cancer vaccine.
Moderna's mRNA flu vaccine, called mFlusiva, has been approved by the FDA and is now available at U.S. pharmacies for this flu season, but only for people age 50 and older. A late-stage trial found it about 27% more effective than a standard flu shot, and it is the first flu vaccine in the U.S. to use mRNA technology.
Moderna President Stephen Hoge said the company remains on track to reach cash breakeven (where money coming in covers money going out) by 2028. The headline flags a big stock move and raises the question of whether a cancer vaccine rally is back on, but the article body is too short to identify a specific catalyst.
Moderna's stock has recovered sharply this year as investors weigh whether the company's cancer pipeline can replace the COVID-19 vaccine business that drove its pandemic-era results. The article notes that after COVID vaccine demand collapsed, Moderna's revenues fell and losses piled up, dragging the stock well below its pandemic highs.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| NTRA | Natera Inc | B- | $53.25B | — | 1.59 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $80.80B | 18.67 | 0.13 | Compare |
| RVMD | Revolution Medicines Inc | B- | $40.93B | — | 1.45 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C | $32.06B | 39.67 | 0.35 | Compare |
| BIIB | Biogen Inc | B+ | $31.84B | 38.15 | 0.12 | Compare |
| VRTX | Vertex Pharmaceuticals Inc | B+ | $121.1B | 29.25 | 0.29 | Compare |
| INSM | Insmed Inc | C- | $26.21B | — | 0.83 | Compare |
| INCY | Incyte Corp | B+ | $25.40B | 15.75 | 0.78 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.